Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.
Mach F, Visseren FLJ, Cater NB, Salhi N, Soronen J, Ray KK, Delgado V, Jukema JW, Laufs U, Zamorano JL, Ros E, Plat J, Gesztes AG, Tokgozoglu L, Packard C, Libby P. Mach F, et al. J Clin Lipidol. 2024 Jul 6:S1933-2874(24)00209-5. doi: 10.1016/j.jacl.2024.07.001. Online ahead of print. J Clin Lipidol. 2024. PMID: 39289123 Review.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Cannon CP, et al. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3. N Engl J Med. 2015. PMID: 26039521 Free article. Clinical Trial.
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Robinson JG, et al. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030. JAMA. 2014. PMID: 24825642 Clinical Trial.
Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes.
Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, Heg D, Nanchen D, Räber L, Klingenberg R, Haller ML, Carballo S, Windecker S, Matter CM, Rodondi N, Mach F, Gencer B. Follonier C, et al. Among authors: mach f. Atheroscler Plus. 2024 Sep 15;58:1-8. doi: 10.1016/j.athplu.2024.09.002. eCollection 2024 Dec. Atheroscler Plus. 2024. PMID: 39351317 Free PMC article.
Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial.
Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Lüscher TF, Taniwaki M, Matter CM, Meier B, Jüni P, Windecker S; COMFORTABLE AMI Trial Investigators. Räber L, et al. JAMA. 2012 Aug 22;308(8):777-87. doi: 10.1001/jama.2012.10065. JAMA. 2012. PMID: 22910755 Clinical Trial.
Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial.
Biccirè FG, Kakizaki R, Koskinas KC, Ueki Y, Häner J, Shibutani H, Lønborg J, Spitzer E, Iglesias JF, Otsuka T, Siontis GCM, Stortecky S, Kaiser C, Ambühl M, Morf L, Ondracek AS, van Geuns RJ, Spirk D, Daemen J, Mach F, Windecker S, Engstrøm T, Lang I, Losdat S, Räber L. Biccirè FG, et al. Among authors: mach f. JAMA Cardiol. 2024 Sep 2:e243200. doi: 10.1001/jamacardio.2024.3200. Online ahead of print. JAMA Cardiol. 2024. PMID: 39221516
Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort.
Johner N, Branca M, Carballo D, Baggio S, Nanchen D, Tessitore E, Räber L, Lüscher TF, Matter CM, Windecker S, Rodondi N, Mach F, Gencer B. Johner N, et al. Among authors: mach f. Eur J Prev Cardiol. 2024 Oct 26:zwae346. doi: 10.1093/eurjpc/zwae346. Online ahead of print. Eur J Prev Cardiol. 2024. PMID: 39454630
Body temperature, systemic inflammation and risk of adverse events in patients with acute coronary syndromes.
van der Stouwe JG, Godly K, Kraler S, Godly J, Matter CM, Wenzl FA, von Eckardstein A, Räber L, Mach F, Obeid S, Templin C, Lüscher TF, Niederseer D; SPUM‐ACS investigators. van der Stouwe JG, et al. Among authors: mach f. Eur J Clin Invest. 2024 Sep 30:e14314. doi: 10.1111/eci.14314. Online ahead of print. Eur J Clin Invest. 2024. PMID: 39350322
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.
Fumagalli RM, Voci D, Bikdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; OVID investigators. Fumagalli RM, et al. Res Pract Thromb Haemost. 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39252826 Free PMC article.
620 results